| Identification | Back Directory | [Name]
Cyclopropanecarboxamide, 1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]- | [CAS]
2227482-41-7 | [Synonyms]
ELOVL1-IN-1
ELOVL1-IN-27
1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide
Cyclopropanecarboxamide, 1-(2-fluorophenyl)-N-[1-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]- | [Molecular Formula]
C18H14F2N4O | [MOL File]
2227482-41-7.mol | [Molecular Weight]
340.33 |
| Chemical Properties | Back Directory | [Boiling point ]
584.1±50.0 °C(Predicted) | [density ]
1.40±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: insol; DMSO: 2 mg/ml; Ethanol: insol; PBS (pH 7.2): insol | [form ]
A crystalline solid | [pka]
12.79±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD)[1]. | [Biological Activity]
ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD)[1].
ELOVL1-IN-1 (compound 87) (1 nM-10 μM; 48 h) reduces the the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B‐lymphocytes, and human microglia[1].
ELOVL1-IN-1 (compound 87) reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout (KO) mice (0.5-64 mg/kg; p.o. once daily for 28 days), wild‐type (WT) rats (30-300 mg/kg; p.o. once daily for 7 days), and cynomolgous monkeys (30 mg/kg; p.o. once daily for 7 days)[1]. | [in vivo]
ELOVL1-IN-1 (compound 87) reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout (KO) mice (0.5-64 mg/kg; p.o. once daily for 28 days), wild‐type (WT) rats (30-300 mg/kg; p.o. once daily for 7 days), and cynomolgous monkeys (30 mg/kg; p.o. once daily for 7 days)[1]. | [storage]
Store at -20°C | [References]
[1]. Charifson PS, et, al. 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels. WO2018107056A1. |
|
|